FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012332062> ?p ?o ?g. }

• W2012332062 endingPage "176" @default.
• W2012332062 startingPage "142" @default.
• W2012332062 abstract "Lisdexamfetamine dimesylate (LDX) is a once-daily medication approved by the US Food and Drug Administration for the management of attention-deficit/hyperactivity disorder (ADHD) in children (aged 6-12 years) and adults.This article reviews the pharmacologic and pharmacokinetic properties, clinical efficacy, and safety profile of LDX.Studies, abstracts, reviews, and consensus statements published in English were identified through computerized searches of MEDLINE (1966-August 2008) and International Pharmaceutical Abstracts (1977-August 2008) using search headings lisdexamfetamine dimesylate, attention-deficit/hyperactivity disorder, NRP 104, NRP104-201, NRP104-301, NRP104-302, NRP104-303, and stimulant. Selected information provided by the manufacturer of LDX was included, as were all pertinent clinical trials. The reference lists of identified articles were also searched for pertinent information. Relevant abstracts presented at annual professional meetings were included as well.Several studies have evaluated the pharmacokinetics of LDX in pediatric patients (6-12 years of age) and healthy adults with ADHD. LDX, a prodrug that is therapeutically inactive until metabolized in the body to dextroamphetamine (d-amphetamine), follows linear pharmacokinetics at therapeutic doses (30-70 mg). The efficacy of LDX in the treatment of ADHD was established on the basis of 1 long-term and 2 short-term controlled clinical trials in children who met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, criteria for ADHD (either the combined or the hyperactive-impulsive subtype) and in 1 clinical trial with adults with ADHD. The efficacy trials in children found significant improvements in scores on the Swanson, Kotkin, Agler, M-Flynn, and Pelham deportment sub-scales, the Permanent Product Measure of Performance (Attempted and Correct), and the ADHD Rating Scale Version IV (ADHD-RS-IV) compared with placebo (all, P < 0.001). In the clinical studies designed to measure duration of effect, LDX, compared with placebo, provided efficacy for a full treatment day, up through and including 6 PM, based on parent ratings (Conners' Parent Rating Scale-Revised Short Form) in the morning, afternoon, and early evening (all, P < 0.001). Data from a long-term, open-label extension study that assessed the safety, tolerability, and efficacy of LDX for up to 12 months found LDX treatment resulted in significant improvement (>60%) from baseline in the ADHD-RS-IV at end point (P < 0.001), with good tolerability. The trial in adults found significant improvements in ADHD-RS scores at end point in patients receiving LDX (30,50, and 70 mg) (P < 0.001 for all active doses); significant improvements in ADHD-RS (using adult prompts) scores were observed at each postbaseline weekly assessment, with improvements noted within the first week in all active treatment arms. Results from human abuse liability studies noted that LDX had lower abuse-related drug-liking scores compared with immediate-release d-amphetamine at equivalent doses. The most common adverse events reported with LDX were typical of amphetamine products and included decreased appetite, insomnia, upper abdominal pain, headache, irritability, weight loss, and nausea.Current evidence supports the efficacy and tolerability of LDX as a treatment option for the management of children (aged 6-12 years) and adults with ADHD. As such, LDX may be an integral part of a total treatment program for ADHD that can include other measures such as psychological, educational, and social interventions." @default.
• W2012332062 created "2016-06-24" @default.
• W2012332062 creator A5018134090 @default.
• W2012332062 date "2009-01-01" @default.
• W2012332062 modified "2023-10-13" @default.
• W2012332062 title "The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults" @default.
• W2012332062 cites W1514128735 @default.
• W2012332062 cites W1977388990 @default.
• W2012332062 cites W1979062064 @default.
• W2012332062 cites W1984719574 @default.
• W2012332062 cites W1992488678 @default.
• W2012332062 cites W1995097711 @default.
• W2012332062 cites W2002338346 @default.
• W2012332062 cites W2006058627 @default.
• W2012332062 cites W2010604180 @default.
• W2012332062 cites W2019810626 @default.
• W2012332062 cites W2024285816 @default.
• W2012332062 cites W2028812376 @default.
• W2012332062 cites W2029569572 @default.
• W2012332062 cites W2032285255 @default.
• W2012332062 cites W2037494394 @default.
• W2012332062 cites W2049863677 @default.
• W2012332062 cites W2056054149 @default.
• W2012332062 cites W2056651884 @default.
• W2012332062 cites W2060729111 @default.
• W2012332062 cites W2073171215 @default.
• W2012332062 cites W2078945716 @default.
• W2012332062 cites W2080229721 @default.
• W2012332062 cites W2081653247 @default.
• W2012332062 cites W2082580890 @default.
• W2012332062 cites W2082888727 @default.
• W2012332062 cites W2083031510 @default.
• W2012332062 cites W2084845073 @default.
• W2012332062 cites W2093104583 @default.
• W2012332062 cites W2094658067 @default.
• W2012332062 cites W2095857831 @default.
• W2012332062 cites W2096603885 @default.
• W2012332062 cites W2098140414 @default.
• W2012332062 cites W2098677721 @default.
• W2012332062 cites W2114290463 @default.
• W2012332062 cites W2122369545 @default.
• W2012332062 cites W2123910896 @default.
• W2012332062 cites W2125347442 @default.
• W2012332062 cites W2129620184 @default.
• W2012332062 cites W2135881689 @default.
• W2012332062 cites W2151487996 @default.
• W2012332062 cites W2154426538 @default.
• W2012332062 cites W2156407203 @default.
• W2012332062 cites W2159881136 @default.
• W2012332062 cites W2160487182 @default.
• W2012332062 cites W2162170558 @default.
• W2012332062 cites W2163050774 @default.
• W2012332062 cites W2164720019 @default.
• W2012332062 cites W2165827672 @default.
• W2012332062 cites W2166577179 @default.
• W2012332062 cites W2167062019 @default.
• W2012332062 cites W2248523920 @default.
• W2012332062 cites W2285134444 @default.
• W2012332062 cites W2320441894 @default.
• W2012332062 cites W2320917318 @default.
• W2012332062 cites W2335460664 @default.
• W2012332062 cites W2601920136 @default.
• W2012332062 cites W2914686075 @default.
• W2012332062 cites W3188631020 @default.
• W2012332062 cites W4243845605 @default.
• W2012332062 cites W4251919166 @default.
• W2012332062 cites W4321429195 @default.
• W2012332062 cites W76668800 @default.
• W2012332062 doi "https://doi.org/10.1016/j.clinthera.2009.01.015" @default.
• W2012332062 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19243715" @default.
• W2012332062 hasPublicationYear "2009" @default.
• W2012332062 type Work @default.
• W2012332062 sameAs 2012332062 @default.
• W2012332062 citedByCount "33" @default.
• W2012332062 countsByYear W20123320622012 @default.
• W2012332062 countsByYear W20123320622013 @default.
• W2012332062 countsByYear W20123320622014 @default.
• W2012332062 countsByYear W20123320622015 @default.
• W2012332062 countsByYear W20123320622016 @default.
• W2012332062 countsByYear W20123320622017 @default.
• W2012332062 countsByYear W20123320622020 @default.
• W2012332062 countsByYear W20123320622023 @default.
• W2012332062 crossrefType "journal-article" @default.
• W2012332062 hasAuthorship W2012332062A5018134090 @default.
• W2012332062 hasConcept C112705442 @default.
• W2012332062 hasConcept C118552586 @default.
• W2012332062 hasConcept C126322002 @default.
• W2012332062 hasConcept C2776145449 @default.
• W2012332062 hasConcept C2777112843 @default.
• W2012332062 hasConcept C2777193897 @default.
• W2012332062 hasConcept C2780557958 @default.
• W2012332062 hasConcept C2780783007 @default.
• W2012332062 hasConcept C513476851 @default.
• W2012332062 hasConcept C535046627 @default.
• W2012332062 hasConcept C71924100 @default.
• W2012332062 hasConcept C98274493 @default.
• W2012332062 hasConceptScore W2012332062C112705442 @default.
• W2012332062 hasConceptScore W2012332062C118552586 @default.

• next